Pharmaceuticals & Therapeutics

Senti Biosciences advances its AML cell therapy to a registrational trial after FDA meeting and a key discovery that quadruples patient response rates.

With a new CFO known for big-ticket financing and IPO readiness, clinical-stage OnCusp Therapeutics is gearing up for its next major growth spurt.

A new pill-only combination drug for acute myeloid leukemia promises to reduce hospital visits and improve quality of life for elderly and unfit patients.

METiS TechBio's stock surged over 170% on its debut, as investors bet big on its AI-powered platform to build the future of precision drug delivery.

A new campaign is challenging perceptions of Alzheimer's, but it's fueled by more than stories. It's a nexus of new drugs, blood tests, and patient advocacy.

The Virginia-based startup landed a major funding round to automate liquid biopsy sample prep, aiming to make cancer detection faster and more reliable.

A biotech firm says it has grown functional human sperm in a lab and created embryos, a huge leap that could change millions of lives and spark ethical debate.

From malaria vaccines to maglev trains, 12 finalists are celebrated for breakthroughs tackling the world's most pressing environmental and health crises.

A new study reveals Efsubaglutide Alfa not only controls diabetes but may also improve the body's own insulin-producing cells, heralding a new era.

The 2026 Giants of Multiple Sclerosis® awards celebrate the multidisciplinary teams shaping the future of MS, from research to rehabilitation.

After two rejections and a dramatic financial restructuring, Atara Biotherapeutics has a clear path to resubmit its key cancer therapy to the FDA.

With cash to last into 2027, Bolt Biotherapeutics focuses all hope on its lead cancer drug, BDC-4182, ahead of crucial Q3 clinical data.

A new strategic alliance brings European cGMP-grade vitamin APIs to the U.S., promising to enhance quality and supply reliability for compounding pharmacies.

From nano-surfactants to pharmaceuticals, SureNano Science is betting its future on a novel obesity drug. Can this microcap survive the big leagues?

Pharma and COVID-response leader John Young joins UCSF's QBI to translate its cutting-edge protein science into transformative therapies and partnerships.

Response Pharmaceuticals unveils promising data on RDX-002, a first-in-class drug aimed at preventing a severe side effect of essential mental health drugs.

Arvinas secures a historic first FDA approval for a PROTAC drug and inks a deal to fuel a deep pipeline targeting cancer and neurodegenerative diseases.

A new report reveals that equipment fires, regulatory hurdles, and subtle operational flaws are emerging as major threats to the clean energy transition.

A new specialty clinic in Philadelphia tackles a nationwide shortage of pet dentists, offering advanced, team-based oral care for common animal ailments.

With demand for blood and plasma soaring, Canadian Blood Services is betting on national pride to solve a critical shortage. But can a new campaign work?